Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)

“…However, there is no evidence or clear consensus on the best adjuvant therapy in pemphigus recalcitrant to corticosteroids. Recently, several reports showed that rituximab was a successful treatment for pemphigus unresponsive to other therapeutic options [6,7,8,9,10,11,12,13,14,15,16,17,18]. Rituximab is a genetically engineered chimeric murine-human monoclonal antibody that targets cells expressing CD20, such as pre-B, immature and mature B-lymphocytes, and induces their depletion in vivo [19,20,21].…”

Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid

“…Furthermore, B cell depletion therapy with anti-CD20 monoclonal antibody turned out to be effective in the management of -5 -autoimmune diseases, including autoimmune blistering diseases [6][7][8][9][10][11][12][13][14][15][16][17][18][19]. Several studies have also demonstrated that cytokines, such as tumor necrosis factor (TNF)-α, play important roles in these blistering diseases, supported by the validity of the treatment with monoclonal anti-TNF-α antibodies in severe PV [20,21].…”

Dermatolojide Rituksimab Kullanımı

“…Leshem ve ark ise 47 pemfiguslu hastayı 2 haftada 1, 1 gram rituksimab infüzyonu ile başarılı şekilde tedavi edebilmiştir (70). Morrison tedaviye dirençli 3 pemfiguslu hastasını rituksimabla tedavi etmiştir (78). Salopek ve ark rituksimabla tedaviye dirençli pemfiguslu bir olguyu tedavi edebilmiştir (79).…”